Circadian Variation of Plasma Homovanillic Acid Levels Is Attentuated by Fluphenazine in Patients With Schizophrenia

Doran, Allen R.; Labarca, Rafael; Wolkowitz, Owen M.; Roy, Alec; Douillet, Patrice; Pickar, David

doi:10.1001/archpsyc.1990.01810180058009

Cited by 45 publications

(15 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This time course has been noted by others as well (Sack et al 1988;Davila et al 1989;Doran et al 1990). It was of interest to deter mine if this diurnal rhythm was affected by haloperidol treatment.…”

Section: Discussionsupporting

confidence: 68%

“…With regard to plasma HV A, these reports are somewhat inconsistent regarding the effects during the fIrst days of neurolep tic treatment, but the fInding of a downward trend over weeks of treatment as reported here is quite uniform (Pickar et al 1984(Pickar et al , 1986Doran et al 1985Doran et al , 1990Chang et al 1988Chang et al , 1990Davila et al 1988;Farde et al 1988;Alfredsson and Wiesel 1989;Bowers et al 1989;David son et al 1991). Another effect of chronic neuroleptic treatment, as noted here, which has also been reported by others is the normal diurnal variation of plasma HV A levels seen in unmedicated patients and control sub jects.…”

Section: Discussionmentioning

confidence: 64%

“…As noted in Table 2, this morning decrease in plasma HV A levels was abolished by the end of the 5th week of haloperidol treatment. This fInding has re cently been published by Doran et al (1990). Its signifI cance with regard to the mechanism of action of halo peridol is unknown.…”

Section: Discussionmentioning

confidence: 98%

“…Another effect of chronic neuroleptic treatment, as noted here, which has also been reported by others is the normal diurnal variation of plasma HV A levels seen in unmedicated patients and control sub jects. A number of investigators have reported that plasma HV A levels decreased during the late morning hours from about 8:00 A.M. to noon (Contreras et al 1988;Davidson et al 1988;Sack et al 1988;Davila et al 1989;Doran et al 1990). Also consistent with this report, others have found that chronic neuroleptic treat ment tends to lessen or abolish this diurnal decline in plasma HV A levels (Davila et al 1989;Doran et al 1990).…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Studies of Catecholamine Metabolism in Schizophrenia/Psychosis-II

Maas

Contreras

Miller

et al. 1993

Neuropsychopharmacol

View full text Add to dashboard Cite

Acutely psychotic schizophrenic patients were maintained on debrisoquin (DBQ) throughout 5 weeks of treatment with haloperidol. Treatment with haloperidol caused initial increases in urinary homovanillic acid (HVA) output that returned toward baseline by the 5th week. During haloperidol treatment, plasma levels of HVA tended to decrease, concurrent with increased renal cltll rance of HV A. Plasma 3-methoxy-4-hydroxyphenyl-

show abstract

Section: Discussionsupporting

confidence: 68%

Section: Discussionmentioning

confidence: 64%

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Studies of Catecholamine Metabolism in Schizophrenia/Psychosis-II

Maas

Contreras

Miller

et al. 1993

Neuropsychopharmacol

View full text Add to dashboard Cite

show abstract

“…Doran et al (1990) showed that patients with schizophrenia with and without the antipsychotic fluphenazine show blunted plasma HVA amplitudes compared to controls. However, medication further decreased amplitudes and reduced circadian rhythmicity in HVA levels and was coupled with an increase in sleep duration.…”

Section: Dopamine and Dopamine Metabolitesmentioning

confidence: 99%

Schizophrenia: the role of sleep and circadian rhythms in regulating dopamine and psychosis

Yates

2016

Reviews in the Neurosciences

View full text Add to dashboard Cite

AbstractSchizophrenia has long been associated with abnormalities in circadian rhythms and sleep. Up until now, there have been no thorough reviews of the potential mechanisms behind the myriad of circadian and sleep abnormalities observed in schizophrenia and psychosis. We present evidence of sleep playing an important role in psychosis predominantly mediated by dopaminergic pathways. A synthesis of both human and animal experimental work suggests that the interplay between sleep and dopamine is important in the generation and maintenance of psychosis. In particular, both animal and human data point to sleep disruption increasing dopamine release and sensitivity. Furthermore, elevated dopamine levels disrupt sleep and circadian rhythms. The synthesis of knowledge suggests that circadian rhythms, dopamine dysregulation, and psychosis are intricately linked. This suggests that treatment of circadian disturbance may be a useful target in improving the lives and symptoms of patients with schizophrenia.

show abstract

Fluphenazine (oral) versus placebo for schizophrenia

Matar

Almerie²

2007

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

The findings in this review confirm much that clinicians and recipients of care already know, but they provide quantification to support clinical impression. Fluphenazine's global position as an effective treatment for psychoses is not threatened by the outcome of this review. However, fluphenazine is an imperfect treatment and If accessible, other inexpensive drugs less associated with adverse effects may be an equally effective choice for people with schizophrenia.

show abstract

Circadian Variation of Plasma Homovanillic Acid Levels Is Attentuated by Fluphenazine in Patients With Schizophrenia

Cited by 45 publications

References 41 publications

Studies of Catecholamine Metabolism in Schizophrenia/Psychosis-II

Studies of Catecholamine Metabolism in Schizophrenia/Psychosis-II

Schizophrenia: the role of sleep and circadian rhythms in regulating dopamine and psychosis

Fluphenazine (oral) versus placebo for schizophrenia

Contact Info

Product

Resources

About